{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:26:44Z","timestamp":1789921604250,"version":"4.0.1"},"posted":{"date-parts":[[2024,6,3]]},"group-title":"Neuroscience","reference-count":50,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Amyloid plaque deposition is recognized as the primary pathological hallmark of Alzheimer\u2019s disease(AD) that precedes other pathological events and cognitive symptoms. Plaque pathology represents itself with an immense polymorphic variety comprising plaques with different stages of amyloid fibrillization ranging from diffuse to fibrillar, mature plaques. The association of polymorphic A\u03b2 plaque pathology with AD pathogenesis, clinical symptoms and disease progression remains unclear. Advanced chemical imaging tools, such as functional amyloid microscopy combined with MALDI mass spectrometry imaging (MSI), are now enhanced by deep learning algorithms. This integration allows for precise delineation of polymorphic plaque structures and detailed identification of their associated A\u03b2 compositions. We here set out to make use of these tools to interrogate heterogenic plaque types and their associated biochemical architecture. Our findings reveal distinct A\u03b2 signatures that differentiate diffuse plaques from fibrilized ones, with the latter showing substantially higher levels of A\u03b2x-40. Notably, within the fibrilized category, we identified a distinct subtype known as coarse-grain plaques. Both in sAD and fAD brain tissue, coarse grain plaques contained more A\u03b2x-40 and less A\u03b2x-42 compared with cored plaques. The coarse grain plaques in both sAD and fAD also showed higher levels of neuritic content including paired helical filaments (PHF-1)\/phosphorylated phospho Tau-immunopositive neurites. Finally, the A\u03b2 peptide content in coarse grain plaques resembled that of vascular A\u03b2 deposits (CAA) though with relatively higher levels of A\u03b21-42 and pyroglutamated A\u03b2x-40 and A\u03b2x-42 species in coarse grain plaques. This is the first of its kind study on spatial\n                  <jats:italic>in situ<\/jats:italic>\n                  biochemical characterization of different plaque morphotypes demonstrating the potential of the correlative imaging techniques used that further increase the understanding of heterogeneous AD pathology. Linking the biochemical characteristics of amyloid plaque polymorphisms with various AD etiologies and toxicity mechanisms is crucial. Understanding the connection between plaque structure and disease pathogenesis can enhance our insights. This knowledge is particularly valuable for developing and advancing novel, amyloid-targeting therapeutics.\n                <\/jats:p>","DOI":"10.1101\/2024.06.03.596890","type":"posted-content","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T19:55:13Z","timestamp":1717444513000},"source":"Crossref","is-referenced-by-count":4,"title":["Chemical signatures delineate heterogeneous amyloid plaque populations across the Alzheimer\u2019s disease spectrum"],"prefix":"10.64898","author":[{"given":"Srinivas","family":"Koutarapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Dulewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Srikrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Szadziewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Michno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammaryn","family":"Lashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-198X","authenticated-orcid":false,"given":"J\u00f6rg","family":"Hanrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024060615000893000_2024.06.03.596890v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01409-2"},{"key":"2024060615000893000_2024.06.03.596890v1.2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00702-012-0801-3","article-title":"Cerebrospinal fluid amyloid-\u03b2 2-42 is decreased in Alzheimer\u2019s, but not in frontotemporal dementia","volume":"119","year":"2012","journal-title":"J Neural Transm (Vienna"},{"key":"2024060615000893000_2024.06.03.596890v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02198-8"},{"key":"2024060615000893000_2024.06.03.596890v1.4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"2024060615000893000_2024.06.03.596890v1.5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/jnc.13645","article-title":"Probing amyloid-beta pathology in transgenic Alzheimer\u2019s disease (tgArcSwe) mice using MALDI imaging mass spectrometry","volume":"138","year":"2016","journal-title":"J Neurochem"},{"key":"2024060615000893000_2024.06.03.596890v1.6","doi-asserted-by":"crossref","first-page":"e0143647","DOI":"10.1371\/journal.pone.0143647","article-title":"Structural Analysis and Aggregation Propensity of Pyroglutamate A\u03b2(3-40) in Aqueous Trifluoroethanol","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"2024060615000893000_2024.06.03.596890v1.7","doi-asserted-by":"crossref","unstructured":"Dickson, D. W . (1999) Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology 246, II6-II15.","DOI":"10.1007\/BF03161076"},{"key":"2024060615000893000_2024.06.03.596890v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(05)70066-5"},{"key":"2024060615000893000_2024.06.03.596890v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00169-5"},{"key":"2024060615000893000_2024.06.03.596890v1.10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R118.003999"},{"key":"2024060615000893000_2024.06.03.596890v1.11","unstructured":"EISAI (2022) Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheiemr\u2019s disease. Eisai Inc., https:\/\/eisai.mediaroom.com\/2022-09-27-LECANEMAB-CONFIRMATORY-PHASE-3-CLARITY-AD-STUDY-MET-PRIMARY-ENDPOINT,-SHOWING-HIGHLY-STATISTICALLY-SIGNIFICANT-REDUCTION-OF-CLINICAL-DECLINE-IN-LARGE-GLOBAL-CLINICAL-STUDY-OF-1,795-PARTICIPANTS-WITH-EARLY-ALZHEIMERS-DISEASE."},{"key":"2024060615000893000_2024.06.03.596890v1.12","doi-asserted-by":"crossref","unstructured":"Hanrieder, J. , Ljungdahl, A. , Falth, M. , Mammo, S. E. , Bergquist, J. and Andersson, M . (2011) L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Molecular & cellular proteomics : MCP 10, M111.009308.","DOI":"10.1074\/mcp.M111.009308"},{"key":"2024060615000893000_2024.06.03.596890v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(92)90033-5"},{"key":"2024060615000893000_2024.06.03.596890v1.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"2024060615000893000_2024.06.03.596890v1.15","doi-asserted-by":"crossref","unstructured":"Hayato, S. , Takenaka, O. , Sreerama Reddy, S. H. , Landry, I. , Reyderman, L. , Koyama, A. , Swanson, C. , Yasuda, S. and Hussein, Z . (2022) Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer\u2019s disease. CPT Pharmacometrics Syst Pharmacol.","DOI":"10.1002\/psp4.12862"},{"key":"2024060615000893000_2024.06.03.596890v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(94)90458-8"},{"key":"2024060615000893000_2024.06.03.596890v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCA.2021.05.011"},{"issue":"194r","key":"2024060615000893000_2024.06.03.596890v1.18","first-page":"e192","article-title":"Changes in amyloid-\u03b2 and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein","volume":"5","year":"2013","journal-title":"Sci Transl Med"},{"key":"2024060615000893000_2024.06.03.596890v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.3063"},{"key":"2024060615000893000_2024.06.03.596890v1.20","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15694"},{"key":"2024060615000893000_2024.06.03.596890v1.21","doi-asserted-by":"crossref","unstructured":"Michno, W. , Nystrom, S. , Wehrli, P. et al. (2019a) Pyroglutamation of amyloid-betax-42 (Abetax-42) followed by Abeta1-40 deposition underlies plaque polymorphism in progressing Alzheimer\u2019s disease pathology. The Journal of biological chemistry.","DOI":"10.1074\/jbc.RA118.006604"},{"key":"2024060615000893000_2024.06.03.596890v1.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.006604"},{"key":"2024060615000893000_2024.06.03.596890v1.23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg4855"},{"key":"2024060615000893000_2024.06.03.596890v1.24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jnc.14888","article-title":"Chemical imaging of evolving amyloid plaque pathology and associated A\u03b2 peptide aggregation in a transgenic mouse model of Alzheimer\u2019s disease","volume":"152","year":"2020","journal-title":"J Neurochem"},{"key":"2024060615000893000_2024.06.03.596890v1.25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jnc.14559","article-title":"Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology","volume":"151","year":"2019","journal-title":"J Neurochem"},{"key":"2024060615000893000_2024.06.03.596890v1.26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2024060615000893000_2024.06.03.596890v1.27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.4.479"},{"key":"2024060615000893000_2024.06.03.596890v1.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0910-3"},{"key":"2024060615000893000_2024.06.03.596890v1.29","doi-asserted-by":"crossref","first-page":"16483","DOI":"10.1039\/D2CP05961D","article-title":"Pyroglutamate-modified amyloid \u03b2(3-42) monomer has more \u03b2-sheet content than the amyloid \u03b2(1-42) monomer","volume":"25","year":"2023","journal-title":"Phys Chem Chem Phys"},{"key":"2024060615000893000_2024.06.03.596890v1.30","doi-asserted-by":"crossref","unstructured":"Nystr\u00f6m, S. , B\u00e4ck, M. , Nilsson, K. P. R. and Hammarstr\u00f6m, P . (2017) Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging. J Vis Exp.","DOI":"10.3791\/56279"},{"key":"2024060615000893000_2024.06.03.596890v1.31","doi-asserted-by":"publisher","DOI":"10.1021\/cb4000376"},{"key":"2024060615000893000_2024.06.03.596890v1.32","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490390607"},{"key":"2024060615000893000_2024.06.03.596890v1.33","doi-asserted-by":"crossref","unstructured":"Rafii, M. S. , Sperling, R. A. , Donohue, M. C. et al. (2022) The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement.","DOI":"10.1002\/alz.12748"},{"key":"2024060615000893000_2024.06.03.596890v1.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1713215114"},{"key":"2024060615000893000_2024.06.03.596890v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30193-4"},{"key":"2024060615000893000_2024.06.03.596890v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(95)90301-1"},{"key":"2024060615000893000_2024.06.03.596890v1.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","article-title":"Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer\u2019s disease","volume":"2","year":"2016","journal-title":"Alzheimers Dement (N Y"},{"key":"2024060615000893000_2024.06.03.596890v1.38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jalz.2016.09.005","article-title":"Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition","volume":"13","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2024060615000893000_2024.06.03.596890v1.39","doi-asserted-by":"publisher","DOI":"10.1021\/bi900818a"},{"key":"2024060615000893000_2024.06.03.596890v1.40","first-page":"503","article-title":"Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer\u2019s disease and Down\u2019s syndrome brains revealed by confocal microscopy","volume":"147","year":"1995","journal-title":"Am J Pathol"},{"key":"2024060615000893000_2024.06.03.596890v1.41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1074069"},{"key":"2024060615000893000_2024.06.03.596890v1.42","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"2024060615000893000_2024.06.03.596890v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0396-2"},{"key":"2024060615000893000_2024.06.03.596890v1.44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"2024060615000893000_2024.06.03.596890v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(96)00811-6"},{"key":"2024060615000893000_2024.06.03.596890v1.46","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"2024060615000893000_2024.06.03.596890v1.47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"2024060615000893000_2024.06.03.596890v1.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1375-y"},{"key":"2024060615000893000_2024.06.03.596890v1.49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neurobiolaging.2019.03.016","article-title":"Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer\u2019s disease","volume":"79","year":"2019","journal-title":"Neurobiol Aging"},{"key":"2024060615000893000_2024.06.03.596890v1.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.06.03.596890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:30:58Z","timestamp":1768458658000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.06.03.596890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1101\/2024.06.03.596890","relation":{},"subject":[],"published":{"date-parts":[[2024,6,3]]},"subtype":"preprint"}}